Dr. Afsaneh Haftbaradaran Mohammadi, MD

Dr. Haftbaradaran Mohammadi practices at Newport Irvine Dialysis in Irvine, California.

Dr. Haftbaradaran Mohammadi's NPI, 1902040009, was assigned on April 21, 2009. Dr. Haftbaradaran Mohammadi graduated from Isfahan University of Medical Sciences in 2004. Dr. Haftbaradaran Mohammadi holds California license A118197.

Dr. Haftbaradaran Mohammadi's primary practice is Newport Irvine Dialysis, at 16305 Sand Canyon Ave, Irvine, CA 92618 in Orange County. The practice phone is (949) 863-1382.

Dr. Haftbaradaran Mohammadi's primary practice is Newport Irvine Dialysis in Irvine, California. Dr. Haftbaradaran Mohammadi is also affiliated with UCI Health - Orange. The medical group on file is Pacific Renal Care. Dmand AI also links Dr. Haftbaradaran Mohammadi to 3 more hospitals, 5 dialysis centers, 2 group practices and clinics, 1 physician office and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Haftbaradaran Mohammadi practices, 12 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Haftbaradaran Mohammadi's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Haftbaradaran Mohammadi is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Haftbaradaran Mohammadi's licenses on file in 2 states: California and Pennsylvania.

Dmand AI lists acute kidney failure, chronic anemia, chronic kidney disease and fluid and electrolyte imbalances among the conditions Dr. Haftbaradaran Mohammadi treats.

CMS data shows 1,004 Medicare services from Dr. Haftbaradaran Mohammadi across 7 procedure codes in 2024, for 191 Medicare patients. Medicare paid $71,344 for them.

CMS counts 191 Medicare patients who saw Dr. Haftbaradaran Mohammadi in 2024. The largest group is 75 to 84, with 72 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 52% are also on Medicaid. Their average risk score is 3.39, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Haftbaradaran Mohammadi's median patient age at 69, with 39% women.

In 2024, Dr. Haftbaradaran Mohammadi wrote 371 Medicare Part D claims for 63 patients. 75% of them were for generic drugs. CMS names the drug for 169 of them, across 10 drugs with 11 or more claims each, at $48,973 in total drug cost. In 2023, CMS named 200 claims across 11 drugs.

Dr. Haftbaradaran Mohammadi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Haftbaradaran Mohammadi as offering telehealth.

CMS Open Payments shows 30 general payments to Dr. Haftbaradaran Mohammadi from 11 drug and device companies from 2018 to 2025. Food and beverage make up the largest share, 98% of the total. Fresenius USA Marketing, Inc. paid the most, $323.

Dr. Haftbaradaran Mohammadi graduated from Isfahan University of Medical Sciences in 2004.

Dr. Haftbaradaran Mohammadi is in network with 15 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.